The management on this company is astonished by the current valuation. In their interpretation of the recent news shares of BVTI should be trading north of $2 a shares. The damage associated with the sale of shares by creditors wasn't anticipated but, as most biotech companies know they have little to do with the streets interpretation of value. As news unfolds over the next few months shares should respond positively.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.